Tamtam Try Tamtam free
CooperCompanies logo

CooperCompanies account plan

Medical device manufacturing

At a glance

CooperCompanies is a medical device group in contact lenses (CooperVision) and fertility and women's health (CooperSurgical); FY2025 net sales $4,092.4 million.

The Cooper Companies (Nasdaq: COO), headquartered in San Ramon, California, is a global medical device company selling in over 130 countries through two segments: CooperVision (contact lenses) and CooperSurgical (fertility and women's health). In FY2025 (year to October 31, 2025) net sales were $4,092.4 million, net income $374.9 million and operating income $682.9 million. It has a workforce of more than 15,000, 52% in the Americas and 42% in EMEA. On October 27, 2026 Al White stepped down as CEO; Executive Chair Walt Rosebrough oversees day-to-day operations until a permanent CEO is appointed.

Business units

Strategic priorities

CooperVision organic growth first
After the strategic review completed on September 9, 2026, investment in CooperVision commercial strengths, innovation and organic growth is the top priority; CooperSurgical prioritises organic growth and operational improvement.
Commercial execution
Cooper is expanding CooperVision's global sales and marketing organisation; the U.S. sales force expansion will cover about 5,000 additional doors, with reps in the field around fiscal Q2 2027.
Faster innovation
New product introductions are being accelerated, with The Vision Centre R&D hub opened on September 23, 2026; launches planned for around 2030 are being pulled forward.
Myopia management and premium dailies
MiSight grew 20% organic in Q3 FY2026 and single-use silicone hydrogel franchises such as MyDay remain a focus.
Cash generation and buybacks
A long-term free cash flow objective exceeding $2.2 billion for FY2026-FY2028, with the buyback authorization raised to $3.0 billion in September 2026.
New CEO and board refresh
A CEO search is under way with Russell Reynolds, and the Board shrinks to seven nominees for 2027, four with extensive medical device experience.

Latest results

In Q3 FY2026 (quarter to July 31, 2026) revenue was $1.066 billion, up 1% reported and organic, and non-GAAP EPS was $1.15 (+4%); GAAP EPS of $2.24 included a $307.2 million discrete UK tax benefit. CooperVision was flat at $717.0 million because of reductions in U.S. channel inventory, while CooperSurgical rose to $349.2 million (+3% organic). Free cash flow was a record $273.0 million. FY2026 guidance was cut to revenue of $4.229-4.252 billion and non-GAAP EPS of $4.51-4.55, and was reaffirmed on October 27, 2026.

Investments and deals

Capital expenditure
FY2025 capex was $362.4 million, of which CooperVision $322.9 million, including investment in distribution and packaging such as a new packaging facility in Puerto Rico.
R&D hub
The Vision Centre, CooperVision's new global R&D innovation hub, opened on September 23, 2026.
Share repurchases
4.9 million shares bought for $339.1 million in Q3 FY2026 and $445 million in the fiscal year so far; authorization raised from $2 billion to $3 billion.
Inventory and logistics
An AI-based inventory control system and a revised logistics approach to support future direct shipping capabilities.

Challenges and risks

Commercial under-coverage
The former CEO said Cooper has fewer salespeople in the field than its competitors and no product in the super premium daily lens segment.
U.S. channel destocking and Asia softness
CooperVision Americas fell 2% in Q3 FY2026 on channel inventory reductions, and Asia Pacific fell 10% on softness in Japan and China.
Paragard competition
A competing non-hormonal IUD has been approved, which the Board cited as a temporary factor behind its valuation disconnect.
Litigation and tax disputes
The embryo culture media recall cost a $272.0 million net litigation charge, and a UK payroll tax dispute carries a possible loss of up to £71.7 million plus interest.
Leadership transition
The new Executive Chair says recent performance has not met expectations while a permanent CEO is sought.

What leadership says

“The Company's recent performance has not met our expectations, and the Board believes decisive action is needed to ensure the Company reaches its long-term potential.”

Walt Rosebrough, Executive Chair · Leadership transition press release, October 27, 2026

“We don't have enough salespeople on the street. We have quite a bit less than our competitors have out there right now.”

Al White, President and CEO (stepped down October 27, 2026) · Q3 FY2026 earnings call, September 9, 2026

“The process identified meaningful opportunities to enhance execution, sharpen our strategic focus and accelerate innovation.”

Al White, President and CEO (stepped down October 27, 2026) · Strategic review completion press release, September 9, 2026

“Our fiduciary duty is to maximize shareholder value, and the Board is collectively aligned that given the offers received, retaining CooperSurgical is the best path forward to creating shareholder value at this time.”

Colleen Jay, Chair · Strategic review completion press release, September 9, 2026

Where a supplier can help

Sales force expansion
The U.S. sales force expansion and the commercial execution priority create needs in recruiting, onboarding, territory planning and sales enablement.
AI targeting and analytics
Cooper is investing in AI-driven targeting and analytics tools for its commercial teams, tied to the commercial execution priority.
Logistics and direct shipping
The revised inventory and logistics approach and future direct shipping open opportunities for fulfilment, packaging and supply-chain software suppliers.
Operational efficiency
Cost-reduction and efficiency programmes at both segments favour suppliers of automation and productivity tools.
R&D and manufacturing platform
Accelerated product launches and The Vision Centre's standardized manufacturing platform need equipment, materials and engineering partners.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like CooperCompanies?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about CooperCompanies

What does CooperCompanies do?

It is a global medical device company with two segments: CooperVision, which makes contact lenses, and CooperSurgical, which serves fertility and women's health.

What is CooperCompanies' revenue?

FY2025 net sales were $4,092.4 million. FY2026 guidance is $4.229-4.252 billion.

How many employees does CooperCompanies have?

A workforce of more than 15,000, selling in over 130 countries.

Who leads CooperCompanies?

Al White stepped down as CEO on October 27, 2026; Executive Chair Walt Rosebrough oversees day-to-day operations while a CEO search runs.

Is CooperCompanies selling CooperSurgical?

No. The Board evaluated a sale with numerous parties and decided in September 2026 to keep CooperSurgical.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)